Imugene Limited

ASX:IMU Stock Report

Market Cap: AU$282.6m

Imugene Future Growth

Future criteria checks 0/6

Imugene is forecast to grow earnings and revenue by 53.4% and 58.2% per annum respectively. EPS is expected to grow by 57.7% per annum. Return on equity is forecast to be -41% in 3 years.

Key information

53.4%

Earnings growth rate

57.7%

EPS growth rate

Biotechs earnings growth15.6%
Revenue growth rate58.2%
Future return on equity-41.0%
Analyst coverage

Low

Last updated07 Nov 2024

Recent future growth updates

Recent updates

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Aug 29
Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Earnings and Revenue Growth Forecasts

ASX:IMU - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027176-8-37-372
6/30/2026N/A-120-89-892
6/30/2025N/A-120-104-1042
6/30/20245-150-111-102N/A
3/31/202410-119-92-81N/A
12/31/202315-89-73-61N/A
9/30/202313-64-52-46N/A
6/30/202312-38-31-31N/A
3/31/202312-39-37-37N/A
12/31/202212-40-42-42N/A
9/30/202213-39-36-36N/A
6/30/202213-38-31-31N/A
3/31/202211-33-27-25N/A
12/31/20218-27-24-20N/A
9/30/20218-23-21-16N/A
6/30/20217-18-19-13N/A
3/31/20217-15-16-12N/A
12/31/20206-12-12-11N/A
9/30/20205-11-12-11N/A
6/30/20204-11-12-10N/A
3/31/20205-10-11-10N/A
12/31/20195-9-10-9N/A
9/30/20195-8-9-8N/A
6/30/20194-8-8-8N/A
3/31/20193-7-7-7N/A
12/31/20183-6-7-6N/A
9/30/20182-5-6-5N/A
6/30/20182-4-5-5N/A
3/31/20181-3N/A-4N/A
12/31/20171-3N/A-3N/A
9/30/20171-3N/A-3N/A
6/30/20171-3N/A-3N/A
3/31/20171-3N/A-3N/A
12/31/20162-3N/A-3N/A
9/30/20162-3N/A-3N/A
6/30/20162-3N/A-3N/A
3/31/20161-3N/A-2N/A
12/31/20151-2N/A-2N/A
9/30/20151-2N/A-2N/A
6/30/20151-2N/A-2N/A
3/31/20151-2N/A-2N/A
12/31/20141-2N/A-2N/A
9/30/20141-2N/A-1N/A
6/30/20141-2N/A-1N/A
3/31/20140-2N/A-1N/A
12/31/20130-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMU is forecast to have no revenue next year.

High Growth Revenue: IMU is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IMU is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 21:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imugene Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Hunter DiamondDiamond Equity Research LLC
Dennis HulmeEdison Investment Research